ARWR
HEALTHCAREArrowhead Pharmaceuticals Inc
AI Insight
What's Moving ARWR Today?
No stock-specific AI insight has been generated for ARWR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$14.30$84.55
$79.90
Fundamentals
Market Cap$11.6B
P/E Ratio48.7
EPS$-2.27
Dividend Yield—
Dividend / Share—
ROE-42.4%
Profit Margin-48.4%
Debt / Equity—
Trading
Volume1.4M
Avg Volume (10D)—
Shares Outstanding140.9M
ARWR News
26 articles- EU approves Arrowhead's REDEMPLO for rare fat disorder FCSStock Titan·Jun 22, 2026
- Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)Yahoo Finance·Jun 22, 2026
- Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D WebinarsYahoo Finance·Jun 18, 2026
- Arrowhead Pharmaceuticals (ARWR) director files Form 3 showing zero share ownershipStock Titan·Jun 18, 2026
- Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains TractionMarketbeat·Jun 5, 2026
- Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 EventsYahoo Finance·Jun 2, 2026
- Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026Yahoo Finance·May 27, 2026
- Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor FocusYahoo Finance·May 26, 2026
- Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) CongressYahoo Finance·May 26, 2026
- Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026Yahoo Finance·May 26, 2026
- Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build MomentumMarketbeat·May 20, 2026
- Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USAYahoo Finance·May 20, 2026
- Director Daniel Apel to offer 100,000 ARWR common shares (NASDAQ: ARWR)Stock Titan·May 20, 2026
- Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts NearMarketbeat·May 14, 2026
- Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Its Recent Share Price MomentumYahoo Finance·May 12, 2026
- ARWR: Multiple Important Clinical Readouts in 2H26Yahoo Finance·May 12, 2026
- Arrowhead (ARWR) Q2 2026 Earnings TranscriptMotley Fool·May 8, 2026
- Arrowhead Pharmaceuticals Q2 Earnings Call HighlightsMarketbeat·May 7, 2026
- Arrowhead Pharmaceuticals Swings to Fiscal Q2 Loss, Revenue Fallsmarketscreener.com·May 7, 2026
- ARROWHEAD PHARMACEUTICALS ($ARWR) Releases Q2 2026 EarningsQuiver Quantitative·May 7, 2026
- Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter ResultsYahoo Finance·May 7, 2026
- Arrowhead and Madrigal sign global licence for MASH RNAi therapyPharmaceutical-technology·May 6, 2026
- Should Madrigal’s ARO-PNPLA3 License Deal Reshape the MASH Strategy for Madrigal Pharmaceuticals (MDGL) Investors?Yahoo Finance·May 6, 2026
- Madrigal outlays $1bn for Arrowhead’s siRNA MASH assetPharmaceutical-technology·May 5, 2026
- Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal PharmaceuticalsYahoo Finance·May 5, 2026
- IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsightGlobeNewswire Inc.·Apr 29, 2026
All 26 articles loaded
Price Data
Open$80.00
Previous Close$79.90
Day High$82.53
Day Low$79.69
52 Week High$84.55
52 Week Low$14.30
52-Week Range
$14.30$84.55
$79.90
Fundamentals
Market Cap$11.6B
P/E Ratio48.7
EPS$-2.27
Dividend Yield—
Dividend / Share—
ROE-42.4%
Profit Margin-48.4%
Debt / Equity—
Trading
Volume1.4M
Avg Volume (10D)—
Shares Outstanding140.9M
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—